ArriVent BioPharma/AVBP

$20.10

-0.24%
-
1D1W1MYTD1YMAX

About ArriVent BioPharma

ArriVent Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. Its lead development candidate, Furmonertinib, and advance a pipeline of novel therapeutics, such as antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Furmonertinib is an oral, highly brain-penetrant, active mutation-selective EGFR inhibitor that targets both classical (exon 19 deletion and L858R) and uncommon EGFR mutations, including exon 20 insertion mutations, as well as HER2 exon 20 insertion mutations. Furmonertinib is an investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor that is developing for the treatment of NSCLC patients across a set of EGFR mutations. It is also focused on development and commercialization of the ARR-002 program.

Ticker

AVBP

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Zhengbin Yao

Employees

40

Headquarters

Newtown square, United States

AVBP Metrics

BasicAdvanced
$673M
Market cap
-
P/E ratio
-
EPS
-
Beta
-
Dividend rate
$673M
$25.95
$14.35
171K
32.823
2.119
2.119

What the Analysts think about AVBP

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
50.25% upside
High $35.00
Low $25.00
$20.10
Current price
$30.20
Average price target

AVBP Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$17M
-17.54%
Profit margin
0%
NaN%

AVBP Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 36.2%
QuarterlyAnnual
Q1 24
Q2 24
Actual
-$0.70
-
Expected
-$1.10
-$0.64
Surprise
-36.2%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for ArriVent BioPharma stock?

ArriVent BioPharma (AVBP) has a market cap of $673M as of May 19, 2024.

What is the P/E ratio for ArriVent BioPharma stock?

The price to earnings (P/E) ratio for ArriVent BioPharma (AVBP) stock is 0 as of May 19, 2024.

Does ArriVent BioPharma stock pay dividends?

No, ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders as of May 19, 2024.

When is the next ArriVent BioPharma dividend payment date?

ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders.

What is the beta indicator for ArriVent BioPharma?

ArriVent BioPharma (AVBP) does not currently have a Beta indicator.

What is the ArriVent BioPharma stock price target?

The target price for ArriVent BioPharma (AVBP) stock is $30.2, which is 50.25% above the current price of $20.1. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell ArriVent BioPharma stock

Buy or sell ArriVent BioPharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing